Avantor Inc. is increasing global capacity for single-use technologies used in the production of biologics and vaccines. In the U.S. and Europe, the company will increase its single-use manufacturing footprint by 30% and double its cleanroom space. The investment will support growing customer demand for monoclonal antibodies (mAbs), novel cell and gene therapies for oncology and other diseases, as well as vaccines, including those for COVID-19.